Medivation investors hoping for a windfall will be disappointed to hear that on December 20, 2012 a California judge ruled

 Court rules Medivation has no IP rights to Aragon Pharmaceuticals ARN 509 $MDVN

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $129 a month (THIS SUBSCRIPTION AUTOMATICALLY BILLS YOUR CREDIT CARD EACH MONTH UNTIL YOU CANCEL) or $327 for 3 months access (does not auto renew), $997 for 12 months access (does not auto renew). Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if a communications professional our Guidance to PR Professionals contained within it.